The study involves pharmacovigilance databases, electronic health records, and published trial evidence to determine infrequent toxicity pattern, confirm organ-specific patterns of injury and detect responses of delayed onset. Mechanical plausibility was achieved with the testing of drug interactions signaling with systematic biochemical laboratory signals, including ALT, creatinine, troponin, and INR. The isolation of regional clusters of adverse events was achieved through reporting networks such as FAERS, VigiBase, EudraVigilance, and they determine genetic predispositions and sociocultural risk factors. In a variety of populations, comparative cohort designs separated true safety signals and spurious associations to improve causal inferences. The outcome demonstrates the relevance of the comorbidity profiling, longitudinal monitoring of exposure and geospatial mapping in identifying high-risk groups of patients. Altogether, the present work demonstrates that the multidimensional secondary strategies may be employed to develop the robust evidence-based regulatory recommendations, clinical decision-making and therapy-specific strategies to improve global pharmacovigilance and patient safety outcomes. ..
Keywords: Adverse events, Toxicity, Hepatotoxicity, Pharmacovigilance, comorbidity
How to cite this article: Mohammad S; Vasudevan A; Jadallah H; Drug safety evaluation using real world adverse event patterns. Int J Drug Deliv Technol. 2025;15(4): 1840-1852, DOI: 10.25258/ijddt.15.4.37